Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Biogen initiates phase I study of BIIB-094 in patients with Parkinson's disease

Sep. 2, 2019

ASCLEPIOS I and II trials of ofatumumab in relapsing MS meet primary endpoint

Aug. 30, 2019

Janssen discloses tau-binding molecules

Aug. 30, 2019

Preclinical and first clinical data for the novel Ox1R antagonist, JNJ-61393215

Aug. 30, 2019

Shanghai Dongxi Zhihui Biological Medicine patents beta-amyloid production inhibitors

Aug. 30, 2019

Denali Therapeutics synthesizes brain-penetrant LRRK2 kinase inhibitors for the treatment of PD

Aug. 30, 2019

First patient enrolled in phase IIa study of sepranolone

Aug. 30, 2019

FDA accepts IND for clinical study of MR-301 for severe traumatic brain injury

Aug. 30, 2019

Discovery of pyridinylimidazoles as brain-penetrant dual kinase inhibitors

Aug. 29, 2019

2,3,6-Trisubstituted pyridine-containing M4 PAM shows selectivity and preclinical efficacy

Aug. 29, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...